



822 S. ROBERTSON BLVD., STE. 312  
 LOS ANGELES, CA 90035  
 TEL: (310) 657-1077 FAX: (310) 657-1053  
 E-MAIL: immunsci@gmail.com

REFERRING PHYSICIAN

\*\*\*\*\*  
 RESEARCH  
 \*\*\*\*\*  
 -

PATIENT NAME

SAMPLE, REPORT

AGE SEX

37Y F

ACCESSION NO.

D.O.B.

COLLECTION DATE

LOG-IN DATE

TEST DATE

REPORT DATE

AAAA11

08/11/1984

11/5/2021

12/21/2021

12/21/2021

12/21/2021

TEST

RESULTS  
 NORMAL ABNORMAL

REFERENCE  
 RANGE

UNITS

AUTOIMMUNE LIVER DIS PNL

ACTIN/SMOOTH MUSCLE IgG

0.52

<20

UNITS

RESULTS REPORTED AS 20.0-30.0 UNITS ARE CONSIDERED EQUIVOCAL

ANTI-MITOCHONDRIAL

0.50

<0.9

INDEX

RESULTS REPORTED AS 0.91 - 1.09 ARE CONSIDERED EQUIVOCAL.  
 RESULTS REPORTED AS >1.11 ARE CONSIDERED POSITIVE.

Anti-actin antibodies are the main component of what have been called smooth muscle antibodies (ASMA). These antibodies display specificity towards the actin component of the cytoskeleton. Anti-actin antibodies are found in 52-85% of patients with AIH or chronic active hepatitis (CAH) and in 22% of patients with primary biliary cirrhosis (PBC). Anti-actin antibodies have been reported, usually in low titers, in 3-18% of sera from the general healthy population.

Anti-Mitochondrial antibodies (AMA) are detected in patients with primary biliary cirrhosis (PBC) a chronic disease characterized by the destruction of the small intrahepatic bile ducts. Progressive duct destruction leads to increasing functional impairment of the liver and transplantation. The etiology of PBC is unknown although a genetic component as well as other factors may be important for the development of the disease. Serological assays are important aids to the recognition and diagnosis of PBC since many antibodies associated with PBC are present before symptoms become evident. Since the presence of AMA can precede the development of symptomatic disease, the ability to identify the presence of markers for PBC can contribute to earlier diagnosis and treatment, and may slow the progression of the disease.

\* \* \* LIMITATIONS \* \*

\*Specimens received as hemolytic, lipemic, bacterially contaminated, or heat inactivated, are rejected for analysis.

Gopal Krishnan, PhD, HCLD (ABB), Lab Director

A.Vojdani, PhD, CLS, Tech Dir